New MRI dye could help doctors see bladder cancer depth without surgery
NCT ID NCT04369560
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new MRI technique that uses two contrast agents (gadobutrol and ferumoxytol) placed directly into the bladder to improve staging of bladder cancer. Researchers will compare MRI images to actual tumor samples from surgery to see if the scan can accurately show how deep the cancer has grown. The study involves 42 adults with bladder tumors who are scheduled for either tumor removal or bladder removal surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gadobutrol and ferumoxytol (contrast agents)
What this could lead to
If successful, this MRI method could help doctors more accurately determine bladder cancer stage without invasive biopsies.
What could go wrong
This is a very early phase 1 study with only 42 people. The new MRI technique may not be more accurate than current methods, and there are risks from the contrast agents and catheter placement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center - Dept of Urology
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••